Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives $11.50 Consensus Price Target from Brokerages

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $14.00.

KLRS has been the subject of several research analyst reports. Citizens Jmp began coverage on shares of Kalaris Therapeutics in a research report on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price target for the company. Wall Street Zen raised shares of Kalaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. Raymond James Financial began coverage on Kalaris Therapeutics in a research report on Tuesday, September 2nd. They issued a “strong-buy” rating for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday.

Hedge Funds Weigh In On Kalaris Therapeutics

A number of large investors have recently made changes to their positions in the business. Woodline Partners LP purchased a new stake in shares of Kalaris Therapeutics in the third quarter worth approximately $1,394,000. Belpointe Asset Management LLC acquired a new position in Kalaris Therapeutics in the 3rd quarter valued at approximately $231,000. Fortis Capital Advisors LLC acquired a new position in Kalaris Therapeutics in the 3rd quarter valued at approximately $231,000. XTX Topco Ltd purchased a new stake in Kalaris Therapeutics in the 2nd quarter worth approximately $65,000. Finally, Bridgeway Capital Management LLC acquired a new stake in shares of Kalaris Therapeutics during the 3rd quarter valued at $130,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Kalaris Therapeutics Trading Down 0.8%

Shares of KLRS opened at $9.58 on Tuesday. The business’s 50-day moving average price is $6.38 and its 200 day moving average price is $4.52. The stock has a market capitalization of $179.15 million, a P/E ratio of -2.54 and a beta of -0.04. Kalaris Therapeutics has a 1-year low of $2.14 and a 1-year high of $12.90.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.02.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.